none
none

CSIRO IS ON A HEALTH KICK

05-09-2017
by 
in 
CSIRO M2 programme

Breakthroughs and remarkable discoveries are expected from the new "M2" programme between CSIRO and Monash University, as the two scientific behemoths collaborate to "bring the best minds and technology together to turn great ideas into a reality for Australia’s flourishing medtech industry". 

As innovation continues to be the watchword for Australian industry, efforts by the government to reinvest in science and technology are continuing apace. 

“From life-changing cochlear implants, to life-saving vaccines, world-first 3D printed bone and tissue replacements, Australia has an incredible track record when it comes to medical technologies and pharmaceuticals,” Senator Arthur Sinodinos said.

“M2 will help to accelerate development of technology like this, not only vital for the improvement of the lives of Australians facing medial challenges, but also leading to job and economic growth for Australia.”

Supported by the Science and Industry Endowment fund, M2 aims to bridge the gap between Australia's many small- and medium-sized medical technology enterprises, and the often-exorbitant cost of prototyping and developing new products. 

M2 will be providing a research ecosystem for these companies, helping to transition new discoveries from the bench to prototyping, pre-clinical testing, industry evaluation and commercialisation.

“M2 leverages some of Australia’s best medtech expertise, experience and equipment,” CSIRO Director of Manufacturing Dr Keith McLean said.

“When a company comes to us we can use CSIRO and MHTP facilities to develop and analyse production scale prototypes, whilst the Monash Biomedical Imaging facility can provide advanced pre-clinical and clinical testing and imaging.”

With global populations ageing and emerging markets seeking better health care, there’s huge growth underway in the MTP sector. It’s expected to be worth almost $3 trillion by 2025, while $18 billion and 28,000 new jobs could be added to the Australian economy over the next eight years.

“Monash is determined to help build a new, globally competitive biomedical industry with our partners,” Monash University Provost and Senior Vice-President Professor Marc Parlange said.

“This initiative will deliver real health benefits to all Australians. Our healthcare spending is expected to almost double to 16 per cent of GDP by 2040. Cheaper and more effective medical solutions are better for our health and Australia’s financial future.”

Related news & editorials

  1. Adaptalift acquires Budget
    11.12.2017
    11.12.2017
    by      In
    Adaptalift Group has completed its acquisition of Budget Forklifts.
    Budget Forklifts was established in 1968 and is the Yale Dealer in Western Australia and Queensland. Adaptalift Group will continue to operate Budget Forklifts as the Yale dealership in those territories.
    Budget Forklifts has more... Read More
  2. 07.12.2017
    07.12.2017
    by      In
    It’s official: Industry Update is on the rise. The November 2017 issue of the magazine was distributed to 19,030 subscribers – a figure confirmed by an independent auditors’ report to the Audited Media Association of Australia (AMAA).
    The figure, which corresponds to a circulation in excess of 76,... Read More
  3. 07.12.2017
    07.12.2017
    by      In
    Amidst a barrage of complaints from consumers and companies alike, NBN Co has announced that it will cease selling services on its hybrid fibre-coaxial (HFC) network.
    This temporary halt in rollout is due to "interference" from Telstra's infrastructure, which was leading to dropouts and... Read More
  4. 07.12.2017
    07.12.2017
    by      In
    Just one year ago pain med brand Nurofen was slugged with a $6 million dollar fine for making false claims about pain relief; now Voltaren is under fire for the exact same issue.
    The ACCC has filed formal proceedings in the Federal Court against GlaxoSmithKline and Novartis, alleging the drugmakers... Read More